Abstract
Immunotherapy has been one of the most important developments in cancer treatment of the past few decades. With the inclusion of immunotherapy in cancer treatment, overall survival rates have increased in some cancers. However, its usage comes with harmful side effects and research has shown that concomitant use of antibiotics has decreased its efficacy. Hence, our study aims to evaluate the risks and benefits of using pembrolizumab with or without concomitant use of antibiotics, in which such evidence can be used for the development of biomarkers for immunotherapy treatment in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
